Chronic Hepatitis B: Essential Guide To Diagnosis, Treatment

Chronic hepatitis B represents a persistent liver infection caused by the hepatitis B virus (HBV), lasting beyond six months and potentially leading to severe complications if unmanaged. This condition affects millions globally, often progressing silently until advanced liver damage occurs.

The Nature of Hepatitis B Virus

The hepatitis B virus targets the liver, entering through bodily fluids such as blood, semen, or vaginal secretions. Transmission occurs via unprotected sexual contact, sharing needles, or perinatal exposure from infected mothers to infants. Unlike acute infections that resolve in most adults, chronic cases develop in up to 90% of infected newborns and 20-40% of those with weakened immunity, like hemodialysis patients.

Once established, HBV integrates into liver cells, causing ongoing inflammation. The virus’s DNA levels in blood, measured as HBV DNA, serve as a key marker for disease activity and treatment decisions. Without intervention, it heightens risks for cirrhosis—scarring that impairs liver function—and hepatocellular carcinoma, a primary liver cancer.

Recognizing Signs and Symptoms

Many with chronic hepatitis B remain asymptomatic for years, earning it the moniker of a “silent killer.” When symptoms emerge, they mirror acute infection but persist or recur: fatigue, abdominal discomfort, joint aches, dark urine, clay-colored stools, nausea, vomiting, fever, and jaundice—yellowing of skin and eyes due to bilirubin buildup.

In advanced stages, complications signal progression:

• Persistent exhaustion and appetite loss
• Spleen enlargement from portal hypertension
• Ascites, fluid accumulation in the abdomen
• Spider angiomas and palmar erythema
• Coagulopathy, easy bruising or bleeding
• Hepatic encephalopathy, confusion from toxin buildup
• Itchiness from bile salt accumulation

Co-infection with hepatitis D worsens outcomes, accelerating cirrhosis in up to 70% of cases. Regular monitoring detects these early, as symptoms alone underrepresent damage.

Risk Factors and Global Burden

Worldwide, over 250 million live with chronic HBV, with highest prevalence in sub-Saharan Africa and East Asia due to perinatal spread. In the U.S., immigration from endemic areas drives cases.

Diagnostic Approaches

Diagnosis combines blood tests and imaging. Core tests include:

• HBsAg (surface antigen): Confirms active infection if positive beyond 6 months
• Anti-HBc (core antibody): Indicates past or current exposure
• HBeAg and anti-HBe: Assess replication activity
• HBV DNA quantification: Measures viral load (>10^5 copies/mL signals high activity)
• Liver enzymes (ALT/AST): Elevated levels (>2x normal) suggest inflammation

Liver biopsy or non-invasive fibrosis scans (e.g., FibroScan) evaluate damage extent. Ultrasound screens for cirrhosis or cancer.

Treatment Strategies

No cure exists, but antivirals suppress replication, halt progression, and reduce cancer risk. Treatment targets those with high viral load, elevated ALT, or fibrosis.

Preferred oral agents:

• Entecavir or Tenofovir: First-line, taken daily indefinitely; high potency, low resistance
• Lamivudine or Adefovir: Older options, higher resistance risk; used in specific cases

Interferon-alpha (injections) suits select patients, promoting HBeAg seroconversion (loss of e-antigen), but side effects limit use, especially in cirrhosis. Response criteria: undetectable HBV DNA, normalized ALT, improved histology.

For decompensated cirrhosis, antivirals bridge to transplant. Most require lifelong therapy; stopping risks relapse.

Monitoring and Disease Phases

Chronic HBV cycles through phases:

• Immune-tolerant: High virus, normal liver enzymes
• Immune-active: High virus/enzymes, inflammation
• Inactive carrier: Low virus/enzymes, minimal damage
• Reactivation: Flares in inactive phases

Six-monthly checks of viral load, ALT, and AFP (cancer marker) with annual ultrasound guide adjustments.

Lifestyle Modifications for Management

Beyond meds, patients should:

• Avoid alcohol to prevent accelerated damage
• Maintain healthy weight; manage fatty liver risks
• Practice safe sex and avoid needle sharing
• Ensure HBV vaccination for household contacts
• Monitor for drug toxicities (e.g., tenofovir on kidneys)

A balanced diet supports liver repair; no specific foods cure HBV.

Prevention: Vaccination and Beyond

The HBV vaccine, given in three doses, prevents infection effectively—universal infant immunization has slashed rates. High-risk adults (e.g., healthcare workers) also vaccinate. Post-exposure: vaccine plus HBIG (immunoglobulin) within 24 hours.

Safe practices curb spread: screened blood products, sterile equipment.

Potential Complications and Prognosis

Untreated, 20% develop cirrhosis or cancer; mortality rises. Treatment improves survival: suppressed virus lowers cancer risk by 50%+. Transplant succeeds for end-stage disease, though reinfection risks persist.

Co-morbidities like HIV or HDV complicate care.

Frequently Asked Questions (FAQs)

Can chronic hepatitis B be cured?

No outright cure, but antivirals control it lifelong, preventing complications.

Is hepatitis B contagious forever?

Chronic carriers shed virus intermittently; infectivity drops with treatment.

Does alcohol worsen chronic HBV?

Yes, it synergizes with HBV to speed cirrhosis.

Who should get vaccinated?

All infants, unvaccinated adults, high-risk groups.

How often is monitoring needed?

Every 6 months for stable cases; more if active.

Outlook for Patients

With vigilant care, most thrive without progression. Early detection via screening saves lives. Consult hepatologists for tailored plans.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb